{"entity":{"id":"nct05511844","kind":"trial","name":"Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of ORM-5029 run by Orum Therapeutics USA, Inc., terminated.","summary":"Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors is a phase 1 interventional study registered as NCT05511844 by Orum Therapeutics USA, Inc., with 25 participants enrolled, started 2022-10-03. Conditions recorded: HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification and HER2 Gene Mutation. Interventions recorded: ORM-5029.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05511844","url":"https://clinicaltrials.gov/study/NCT05511844"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["orm-5029"],"companies":["orum-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05511844","phase":"1","setting":"Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors","sponsor":"Orum Therapeutics USA, Inc.","enrolled":25,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05511844/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"orm-5029","kind":"drug","name":"ORM-5029","route":"/drugs/orm-5029/"}],"company":[{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/"}]}}